| Issue | Title | |
| Vol 2023, No 5 (2023) | Assertio to Acquire Spectrum Pharmaceuticals for Up to US$291 M | Abstract pdf html |
| Ashish Tripathi | ||
| Vol 2014, No 11 (2014) | Astellas Affirms Interest in Genetic Diseases by Partnering with Proteostasis Therapeutics | Abstract |
| Heather Cartwright | ||
| Vol 2017, No 4 (2017) | Astellas Acquires Fezolinetant for Menopausal Symptoms in Ogeda Acquisition | Abstract pdf html |
| Natasha Piper | ||
| Vol 2013, No 4 (2013) | Astellas Adds to Antibody-Drug Conjugate Capabilities with Ambrx Collaboration | Abstract |
| Heather Cartwright | ||
| Vol 2017, No 3 (2017) | Astellas Advances its Vaccine Ambitions with Affinivax’s Pneumococcal Candidate | Abstract html pdf |
| Jasmine Kalsi | ||
| Vol 2016, No 11 (2016) | Astellas Advances Oncology Strategy with US$1.4 B Ganymed Purchase | Abstract html pdf |
| Jawala Prasad | ||
| Vol 2010, No 3 (2010) | Astellas Aims for Global Oncology Position through OSI | Abstract |
| PharmaDeals Analyst | ||
| Vol 2008, No 94 (2008) | Astellas and CoMentis Enter into Deal for Novel Alzheimer's Drug | Abstract pdf html |
| The PharmaDeals Team | ||
| Vol 2009, No 11 (2009) | Astellas and Medivation in Pact for Prostate Cancer Drug | Abstract |
| Taskin Ahmed | ||
| Vol 2009, No 1 (2009) | Astellas Bids US$1 B for CV Therapeutics | Abstract pdf html |
| Taskin Ahmed | ||
| Vol 2008, No 91 (2008) | Astellas Builds Up Antibodies Pipeline | Abstract pdf |
| Business Review Editor | ||
| Vol 2020, No 1 (2020) | Astellas Continues Gene and Cell Therapy Acquisition Trend with Xyphos Buy | Abstract html pdf |
| Jawala Prasad | ||
| Vol 2011, No 7 (2011) | Astellas Divests Prosidion’s DPP-IV Inhibitor Patent Assets to Royalty Pharma | Abstract |
| Heather Cartwright | ||
| Vol 2023, No 8 (2023) | Astellas Enters into Collaborations with PeptiDream and Cullgen to Advance Targeted Protein Degraders | Abstract pdf html |
| Ashish Tripathi | ||
| Vol 2006, No 72 (2006) | Astellas Enters into Yet Another Agreement | Abstract pdf |
| Business Review Editor | ||
| Vol 2018, No 12 (2018) | Astellas Exercises Option to Acquire Potenza Therapeutics | Abstract pdf html |
| Michelle Liu | ||
| Vol 2011, No 3 (2011) | Astellas Gains Ex-Asia Rights to Tivozanib from AVEO in Potential US$1.4 B Deal | Abstract |
| Heather Cartwright | ||
| Vol 2019, No 7 (2019) | Astellas Gains Hearing Disorder Therapy from Frequency Therapeutics | Abstract pdf html |
| Michelle Liu | ||
| Vol 2005, No 66 (2005) | Astellas Joins Theravance in Fight against MRSA | Abstract pdf |
| Business Review Editor | ||
| Vol 2011, No 2 (2011) | Astellas Licenses Regional Rights to Optimer Pharmaceuticals’ Antibiotic for Clostridium Difficile Infection | Abstract |
| Heather Cartwright | ||
| Vol 2019, No 9 (2019) | Astellas Licenses RIKEN’s aAVC Cell Therapy Technology for US$9.4 M Upfront | Abstract pdf html |
| Michelle Liu | ||
| Vol 2020, No 1 (2020) | Astellas Partners with Adaptimmune on “Off-the-shelf” Cell Therapies | Abstract html pdf |
| Michelle Liu | ||
| Vol 2021, No 12 (2021) | Astellas Partners with Dyno Therapeutics for Gene Therapy Technology | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2010, No 3 (2010) | Astellas Partnership Offsets Ceftobiprole Setback for Basilea | Abstract |
| PharmaDeals Analyst | ||
| Vol 2024, No 10 (2024) | Astellas Pays US$30 M Upfront for AviadoBio’s AAV-based Gene Therapy AVB-101 | Abstract pdf html |
| Shikha Kashyap | ||
| Vol 2015, No 10 (2015) | Astellas Pays US$300 M Upfront to Access Immunomic’s LAMP-vax™ Platform | Abstract html |
| Heather Cartwright & Sayani Datta | ||
| Vol 2023, No 5 (2023) | Astellas Pharma to Acquire Iveric Bio for US$5.9 B | Abstract pdf html |
| Ayush Saxena | ||
| Vol 2019, No 12 (2019) | Astellas Pushes Further into Gene Therapy Field with US$3 B Audentes Buy | Abstract pdf html |
| Michelle Liu | ||
| Vol 2008, No 100 (2008) | Astellas Receives Worldwide Commercial Rights to Major Preclinical Programme | Abstract pdf html |
| Sally Mardikian PhD | ||
| Vol 2022, No 11 (2022) | Astellas Turns to AAV-based Gene Therapy with Taysha Gene Therapies Collaboration Deal | Abstract html pdf |
| Ashish Tripathi | ||
| Vol 2013, No 9 (2013) | Astex Accepts Takeover Offer from Otsuka Regarded As Too Low By Many | Abstract |
| Heather Cartwright | ||
| Vol 2005, No 64 (2005) | Astex Continues to Sign with Big Pharma | Abstract pdf |
| Business Review Editor | ||
| Vol 2006, No 67 (2006) | Astex Licenses Lead Candidates to Novartis | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 35 (2003) | Astex Technology | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 35 (2003) | Astex Technology: Platform Technology Commericalization Methods | Abstract |
| Business Review Editor | ||
| Vol 2010, No 1 (2010) | AstraZeneca Acquires Novexel to Firm Up Anti-infectives Portfolio | Abstract |
| Taskin Ahmed | ||
| Vol 2013, No 10 (2013) | AstraZeneca Acquires Spirogen for Next-Generation Antibody-Drug Conjugate Platform | Abstract |
| Heather Cartwright | ||
| Vol 2022, No 7 (2022) | AstraZeneca Acquires TeneoTwo in US$1.27 B Deal | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2012, No 4 (2012) | AstraZeneca and Amgen Collaborate to Develop and Commercialise Amgen’s Clinical Inflammation Portfolio | Abstract |
| Heather Cartwright | ||
| Vol 2004, No 44 (2004) | AstraZeneca and Array BioPharma Sign Oncology Agreement | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 63 (2005) | AstraZeneca and Early-Stage Deal Making | Abstract pdf |
| Business Review Editor | ||
| Vol 2014, No 10 (2014) | AstraZeneca and Eli Lilly Partner to Develop BACE Inhibitor in Risk-Sharing Deal | Abstract |
| Heather Cartwright | ||
| Vol 2007, No 84 (2007) | AstraZeneca and MedImmune: A Match Made in Biologics Heaven? | Abstract pdf |
| Business Review Editor | ||
| Vol 2009, No 6 (2009) | AstraZeneca and Merck in Anticancer Collaboration | Abstract |
| Taskin Ahmed | ||
| Vol 2017, No 5 (2017) | AstraZeneca and Pieris Collaborate on Inhaled Treatment for Asthma | Abstract pdf html |
| Natasha Piper | ||
| Vol 2011, No 7 (2011) | AstraZeneca and PTC Therapeutics Sign Cancer Drug Discovery Pact | Abstract |
| Heather Cartwright | ||
| Vol 2010, No 2 (2010) | AstraZeneca and Rigel in a US$1.2 B Deal for Rheumatoid Arthritis | Abstract |
| Taskin Ahmed | ||
| Vol 2017, No 9 (2017) | AstraZeneca and Takeda Partner on Development of Parkinson’s Candidate | Abstract pdf html |
| Natasha Piper | ||
| Vol 2010, No 5 (2010) | AstraZeneca and TB Alliance Collaborate to Address TB | Abstract |
| Debbie Tranter | ||
| Vol 2013, No 1 (2013) | AstraZeneca and Vanderbilt University Partner to Develop Drugs for Major Brain Disorders | Abstract |
| Heather Cartwright | ||
| Vol 2014, No 1 (2014) | AstraZeneca Becomes Immunocore’s Third Big Pharma Collaborator | Abstract |
| Heather Cartwright | ||
| Vol 2012, No 8 (2012) | AstraZeneca Becomes Regulus Therapeutics’ Third Big Pharma Collaborator | Abstract |
| Heather Cartwright | ||
| Vol 2015, No 5 (2015) | AstraZeneca Bolsters Immuno-Oncology Portfolio via Deals with Celgene and Innate Pharma | Abstract |
| Heather Cartwright & Smita Mishra | ||
| Vol 2020, No 12 (2020) | AstraZeneca Bolsters Immunology Footprint with US$39 B Alexion Buyout | Abstract pdf html |
| Michelle Liu, | ||
| Vol 2013, No 6 (2013) | AstraZeneca Bolsters Late-Stage Cardiovascular Disease Pipeline with Omthera Pharmaceuticals Purchase | Abstract |
| Heather Cartwright | ||
| Vol 2022, No 12 (2022) | AstraZeneca Bolsters Pipeline with Neogene Therapeutics and C4X Discovery Deals | Abstract pdf html |
| Lucy Haggerty & Amit Kaushik | ||
| Vol 2014, No 9 (2014) | AstraZeneca Boosts Respiratory Business with US$2.1 B Almirall Deal | Abstract |
| Heather Cartwright | ||
| Vol 2024, No 3 (2024) | AstraZeneca Buys Fusion Pharmaceuticals for US$2 B | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2013, No 5 (2013) | AstraZeneca Continues Early-Stage Deal-Making Spree with Alchemia Deal | Abstract |
| Heather Cartwright | ||
| Vol 2018, No 11 (2018) | AstraZeneca Expands Immuno-Oncology Collaboration with Innate Pharma | Abstract pdf html |
| Jasmine Kalsi & Michelle Liu | ||
| Vol 2008, No 103 (2008) | AstraZeneca Expands One Deal and Terminates Another | Abstract pdf html |
| Helen Scrutton | ||
| Vol 2003, No 42 (2003) | AstraZeneca Extends Early-Stage Oncology Pipeline | Abstract pdf |
| Business Review Editor | ||
| Vol 2010, No 3 (2010) | AstraZeneca Follows Other Big Pharma in Forging Emerging Markets Alliances | Abstract |
| PharmaDeals Analyst | ||
| Vol 2012, No 9 (2012) | AstraZeneca Forms Joint Venture with Wuxi AppTec to Accelerate Biologics Development in China | Abstract |
| Heather Cartwright | ||
| Vol 2007, No 89 (2007) | AstraZeneca Gets Verus’ Asthma Assets | Abstract pdf |
| Business Review Editor | ||
| Vol 2013, No 4 (2013) | AstraZeneca Highlights R&D Growth Strategy via Collaborations with BIND Therapeutics and Horizon Discovery | Abstract |
| Heather Cartwright | ||
| Vol 2009, No 12 (2009) | AstraZeneca in Blockbuster Anti-depressant Deal | Abstract |
| Taskin Ahmed | ||
| Vol 2009, No 10 (2009) | AstraZeneca Inks Deal with Nektar | Abstract |
| Taskin Ahmed | ||
| Vol 2018, No 4 (2018) | AstraZeneca Licenses Preclinical NASH Candidate from Partner Ionis | Abstract pdf html |
| Heather Cartwright | ||
| Vol 2012, No 4 (2012) | AstraZeneca Looks to Replenish Late-Stage Pipeline with US$1.26 B Ardea Biosciences Acquisition | Abstract |
| Heather Cartwright | ||
| Vol 2017, No 4 (2017) | AstraZeneca Out-licenses US Rights for its COPD Drugs to Circassia | Abstract pdf html |
| Jasmine Kalsi | ||
| Vol 2015, No 12 (2015) | AstraZeneca Outbids Actelion to Land ZS Pharma | Abstract PDF HTML |
| Heather Cartwright & Keshav Mahawar | ||
| Vol 2019, No 4 (2019) | AstraZeneca Partners Again with Daiichi Sankyo for its ADC Cancer Treatment | Abstract pdf html |
| Michelle Liu | ||
| Vol 2021, No 12 (2021) | AstraZeneca Pays US$200 M Upfront for Ionis’ Rare Disease Drug | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2013, No 4 (2013) | AstraZeneca Places US$240 M Bet on Moderna Therapeutics’ mRNA Technology | Abstract |
| Heather Cartwright | ||
| Vol 2017, No 8 (2017) | AstraZeneca Signs Massive US$8.5 B Oncology Collaboration with Merck & Co Following Trial Failure | Abstract pdf html |
| Daniel Roberts & Natasha Piper | ||
| Vol 2012, No 7 (2012) | AstraZeneca Signs Second Licence Agreement with Rigel for Preclinical Asthma Drug | Abstract |
| Heather Cartwright | ||
| Vol 2012, No 7 (2012) | AstraZeneca Signs Two Deals to Advance its Virtual Neuroscience R&D Strategy | Abstract |
| Heather Cartwright | ||
| Vol 2012, No 1 (2012) | AstraZeneca Signs Two Deals to Reinforce its Pipeline After Development Setbacks | Abstract |
| Heather Cartwright | ||
| Vol 2020, No 6 (2020) | AstraZeneca Signs US$1.2 B RNA Modification Partnership with Accent Therapeutics | Abstract pdf html |
| Michelle Liu | ||
| Vol 2020, No 7 (2020) | AstraZeneca Signs US$6 B ADC Collaboration with Daiichi Sankyo for DS-1062 | Abstract pdf html |
| Michelle Liu | ||
| Vol 2016, No 10 (2016) | AstraZeneca Streamlines Portfolio with Four More Externalisation Deals | Abstract pdf html |
| Keshav Mahawar | ||
| Vol 2013, No 7 (2013) | AstraZeneca Strengthens Core Respiratory Business with US$1.15 B Pearl Therapeutics Purchase | Abstract |
| Heather Cartwright | ||
| Vol 2011, No 12 (2101) | AstraZeneca Strengthens its Position in China with Guangdong BeiKang Pharmaceutical Acquisition | Abstract |
| Heather Cartwright | ||
| Vol 2005, No 55 (2005) | AstraZeneca Takes Stake in Cambridge Antibody Technology alongside Antibody Discovery Alliance | Abstract pdf |
| Business Review Editor | ||
| Vol 2006, No 72 (2006) | AstraZeneca to Acquire Cambridge Antibody Technology | Abstract pdf |
| Business Review Editor | ||
| Vol 2022, No 10 (2022) | AstraZeneca to Acquire LogicBio for US$68.2 M | Abstract pdf html |
| Ashish Tripathi | ||
| Vol 2013, No 2 (2013) | AstraZeneca to Evaluate Orexo Respiratory Programme Previously Partnered with Janssen | Abstract |
| Heather Cartwright | ||
| Vol 2006, No 68 (2006) | AstraZeneca’s Christmas Shopping Spree | Abstract |
| Business Review Editor | ||
| Vol 2006, No 78 (2006) | AstraZeneca’s Disposal of the Humira® Royalty Stream to Royalty Pharma | Abstract |
| Business Review Editor | ||
| Vol 2011, No 10 (2011) | AstraZeneca’s MedImmune In-Licenses Pfizer’s Tremelimumab | Abstract |
| Heather Cartwright | ||
| Vol 2010, No 1 (2010) | AstraZeneca’s Tie-up with Dako to Advance in Personalised Medicine | Abstract |
| Taskin Ahmed | ||
| Vol 2010, No 1 (2010) | Athersys and Pfizer Sign Global Stem Cell Agreement | Abstract |
| Taskin Ahmed | ||
| Vol 2020, No 4 (2020) | Atomwise Signs US$1 B Drug Discovery Deal with Bridge Biotherapeutics | Abstract pdf html |
| Pratika Pahwa | ||
| Vol 2003, No 37 (2003) | Atugen AG | Abstract pdf |
| Business Review Editor | ||
| Vol 2018, No 9 (2018) | Aurobindo to Bolster Generics Portfolio with US$1 B Sandoz Deal | Abstract pdf html |
| Michelle Liu & Keval Haria | ||
| Vol 2014, No 10 (2014) | Auxilium Drops QLT and Accepts Sweetened US$2.6 B Takeover Bid from Endo | Abstract |
| Heather Cartwright | ||
| Vol 2007, No 82 (2007) | Avalon Enters into Collaborative R&D Deal Worth a Potential US$200 M | Abstract pdf |
| Business Review Editor | ||
| Vol 2013, No 2 (2013) | Avalon Ventures’ Afraxis Licenses Entire Drug Portfolio to Genentech | Abstract |
| Heather Cartwright | ||
| Vol 2012, No 3 (2012) | Avanir Licenses Concert’s Deuterium-Modified Dextromethorphan Products in Potential US$200 M Deal | Abstract |
| Heather Cartwright | ||
| 501 - 600 of 2581 Items | << < 1 2 3 4 5 6 7 8 9 10 > >> | |